The POCT Molecular Diagnostics industry trends over the past 18 months have been defined by a surge in decentralized lab-in-a-cartridge systems and a pivot from COVID-only menus to multiplex respiratory syndromic panels. In March 2023, Cepheid closed its $300 M buy-out of LGC’s T-COR 8™ platform, instantly adding CLIA-waived sample-to-answer capability for small hospitals and urgent-care chains. Thermo Fisher deepened the consolidation wave in July by acquiring The Binding Site’s point-of-care division, betting on its miniaturized qPCR optics to shorten a four-target assay to 12 minutes. Partnerships are equally strategic: Visby Health and Walgreens launched a joint pilot that embeds disposable palm-top PCR stations inside 85 retail clinics, cutting flu A/B & RSV result times by 70 % versus send-outs. Regulatory tailwinds accompanied the activity; the FDA’s re-classification of certain multiplex POCT nucleic-acid tests to Class II (Jan 2024) is expected to trim 510(k) review cycles by six months, accelerating commercialization for start-ups. Venture funding, though tighter, still rewarded differentiation—Fluxergy secured $60 M Series C in October to scale its multispectral card into dairy and aquaculture labs, while Molbio’s $50 M raise (Jan 2024) will fund a 30-country rollout of battery-operated Truelab™ systems for African markets. Consumer demand is shifting toward at-home self-collection with telehealth follow-ups; Cue Health responded by unveiling a flu-RSV-COVID combo cartridge compatible with its existing countertop reader, targeting retail pharmacies for winter 2024. Collectively, these moves signal a maturing ecosystem focused on menu diversification, regulatory efficiency, and last-mile access.
